| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | 0.039 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |